Hernix is a kinase inhibitor indicated for:

  • Treatment of adult patients with early stage HER2 overexpressed breast cancer.
  • Hernix can reduce risk of recurrence following Tastuzumab based therapy.
  • Improve disease free survival
  • Significant treatment benefit at 5 years.

It is an oral tablet production available in the strength of 40 mg.

This product is only for export.